Zai Lab (ZLAB)
NASDAQ:ZLAB
Top Page
Zai Lab
(NASDAQ:ZLAB)
Select Model
Select Model
Rating:51Neutral
Price Target:
$21.50
▲(3.97% Upside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by persistent cash burn and ongoing losses despite improving revenue and margins, with some added balance-sheet deterioration risk from rising debt and shrinking equity. Earnings call commentary was a positive offset due to strong cash, operating leverage improvements, and multiple pipeline/launch catalysts, while technicals are mildly supportive near term but still weak over longer timeframes. Valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Sustained revenue scaling
Meaningful multi-year revenue growth demonstrates durable commercial traction and successful product penetration across multiple franchises. Scaling sales provide a foundation for incremental operating leverage, support continued investment in launches and global trials, and reduce execution risk over the next 2–6 months.
Negative Factors
Persistent negative cash flow
Consistently negative operating and free cash flow indicate the business is not yet self‑funding and remains dependent on external financing or partnerships. Continued cash burn heightens refinancing and dilution risk if commercial ramps or approvals are delayed, pressuring sustainability beyond the current runway.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue scaling
Meaningful multi-year revenue growth demonstrates durable commercial traction and successful product penetration across multiple franchises. Scaling sales provide a foundation for incremental operating leverage, support continued investment in launches and global trials, and reduce execution risk over the next 2–6 months.
Read all positive factors
Zai Lab (ZLAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.35B
Dividend YieldN/A
Average Volume (3M)711.58K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth23.73%
EPS Growth30.16%
CountryUS
Employees1,869
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding113,412,800
10 Day Avg. Volume658,920
30 Day Avg. Volume711,580
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)2.70
Price to Sales (P/S)4.20
P/FCF Ratio-12.16
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit6.67
Enterprise Value/Ebitda-11.35
Forecast
1Y Price Target
$34.96Price Target Upside69.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.74
Revenue Forecast (FY)$498.66M
Zai Lab Business Overview & Revenue Model
Company Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-mo...
How the Company Makes Money
Zai Lab primarily makes money through (1) product sales of its commercial-stage medicines in its licensed or owned territories, and (2) collaboration-related revenue tied to partnerships (e.g., licensing arrangements), which can include upfront pa...
Zai Lab Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and R&D momentum: double-digit revenue growth (Q4 +17%, FY +15%), a solid cash balance ($790M), improved operating leverage (R&D -6%, SG&A -12% Q4 / -7% FY), and rapid advancement of high-impact global programs (notably zoci's rapid move to Phase III and encouraging intracranial activity). Management also outlined several near-term commercial launches and late-stage regional catalysts. Offsetting these positives were near-term commercial and pricing headwinds (NRDL renewal effects, hospital procurement timing), supply constraints earlier in the year, generic competition in certain categories, and some uncertainty around 2026 guidance and regulatory/enrollment timing for global registrational programs. On balance, the highlights—particularly the strong financial momentum, large pipeline milestones, and robust cash runway—substantially outweigh the lowlights, though execution and regulatory risks remain.Positive Updates
Revenue Growth (Q4 and Full Year 2025)
Fourth quarter total revenue of $127.6M, up 17% year-over-year; full year 2025 total revenue of $460.2M, up 15% year-over-year.
Negative Updates
Short-term Commercial Dynamics and Pricing Pressure
Q4 VYVGART revenues were impacted by channel dynamics related to NRDL renewal and hospital purchasing patterns. Management flagged near-term measured growth for VYVGART in 2026 due to pricing dynamics, competition and potential IV price adjustments and rebate dynamics.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Growth (Q4 and Full Year 2025)
Fourth quarter total revenue of $127.6M, up 17% year-over-year; full year 2025 total revenue of $460.2M, up 15% year-over-year.
Read all positive updates
Company Guidance
Management framed 2026 as a year of execution and preparation and gave several quantitative guideposts: Q4 revenue was $127.6M (+17% YoY) and full‑year 2025 revenue was $460.2M (+15% YoY); R&D expense declined 6% YoY, SG&A fell 12% in Q4 and 7% for the full year, loss from operations improved 19% to $229.4M (improving 25% on an adjusted basis excluding non‑cash items), and cash totaled $790M at year‑end. They did not provide full‑year 2026 revenue guidance because of moving pieces (VYVGART IV price adjustment, rebate dynamics and hospital purchasing), but expect measured near‑term growth from VYVGART, continued strength in ZEJULA and XACDURO, and planned launches (KarXT commercial launch/COBENFY in Q2 2026; TIVDAK later in 2026) with modest incremental SG&A for launches and R&D broadly stable. Key clinical milestones and timelines included zoci moving from IND to global Phase III in <2 years with a ~480‑patient registrational study (China ~1/3, U.S. ~30%), an 80% ORR reported in 10 patients with untreated brain mets, plans for a potential accelerated submission in 2027 and first global approval in 2028 plus a first‑line pivotal study this year; additional 2026 catalysts cited were zoci data in brain mets/NEC/1L SCLC, first‑in‑human ZL‑1503 data, a povetacicept interim for IgAN in H1 2026, REVEAL‑1 topline in Q1 2026 and REVEAL‑2 in Q2 2026, and expected China approval for TIVDAK in H1 2026.Zai Lab Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
60
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 460.16M | 398.99M | 266.72M | 215.04M | 144.31M |
| Gross Profit | 269.64M | 251.13M | 170.90M | 141.02M | 92.07M |
| EBITDA | -158.25M | -234.57M | -365.11M | -434.84M | -689.46M |
| Net Income | -175.54M | -257.10M | -334.62M | -443.29M | -704.47M |
Balance Sheet | |||||
| Total Assets | 1.17B | 1.19B | 1.04B | 1.22B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 689.57M | 779.67M | 806.45M | 1.01B | 1.41B |
| Total Debt | 224.26M | 153.47M | 15.15M | 20.39M | 15.54M |
| Total Liabilities | 456.88M | 344.86M | 240.18M | 174.54M | 230.00M |
| Stockholders Equity | 715.50M | 840.90M | 796.12M | 1.05B | 1.38B |
Cash Flow | |||||
| Free Cash Flow | -158.89M | -276.39M | -206.67M | -392.63M | -568.18M |
| Operating Cash Flow | -150.79M | -214.87M | -198.18M | -367.64M | -549.23M |
| Investing Cash Flow | 307.87M | -375.19M | -10.78M | 420.02M | 249.96M |
| Financing Cash Flow | 72.35M | 349.89M | -6.43M | -1.73M | 820.20M |
Zai Lab Technical Analysis
Positive
20.68
Price Trends
18.84
Positive
18.83
Positive
25.69
Negative
Market Momentum
0.54
Negative
61.34
Neutral
87.50
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZLAB, the sentiment is Positive. The current price of 20.68 is above the 20-day moving average (MA) of 19.04, above the 50-day MA of 18.84, and below the 200-day MA of 25.69, indicating a neutral trend. The MACD of 0.54 indicates Negative momentum. The RSI at 61.34 is Neutral, neither overbought nor oversold. The STOCH value of 87.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZLAB.
Zai Lab Risk Analysis
Zai Lab disclosed 101 risk factors in its most recent earnings report. Zai Lab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zai Lab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $7.57B | 34.84 | 18.69% | ― | 54.51% | 275.94% | |
71 Outperform | $3.71B | 11.57 | 41.90% | ― | 12.69% | 100.80% | |
67 Neutral | $5.69B | 8.85 | -362.44% | ― | 97.54% | ― | |
64 Neutral | $6.72B | -16.04 | -55.42% | ― | -76.96% | -425.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.35B | -9.68 | -22.81% | ― | 23.73% | 30.16% |
* Healthcare Sector Average
ZLAB
Zai Lab
20.68
-8.86
-29.99%
ACAD
ACADIA Pharmaceuticals
21.74
7.16
49.11%
PTCT
PTC Therapeutics
68.69
25.71
59.82%
KRYS
Krystal Biotech
259.00
94.00
56.97%
ACLX
Arcellx Inc
114.83
55.68
94.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.